Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Herniarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.84 |
| ▸ | CA9 | Q16790 | 5/20 | 0.84 |
| ▸ | CA12 | O43570 | 4/20 | 0.84 |
| ▸ | HPGD | P15428 | 3/20 | 0.84 |
| ▸ | CA1 | P00915 | 2/20 | 0.84 |
| ▸ | CA4 | P22748 | 2/20 | 0.84 |
| ▸ | CA6 | P23280 | 2/20 | 0.84 |
| ▸ | CA5A | P35218 | 2/20 | 0.84 |
| ▸ | CA7 | P43166 | 2/20 | 0.84 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.84 |
| ▸ | CA3 | P07451 | 1/20 | 0.84 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.84 |
| ▸ | POLB | P06746 | 3/20 | 0.69 |
| ▸ | GAA | P10253 | 3/20 | 0.69 |
| ▸ | GLA | P06280 | 2/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | GBA1 | P04062 | 1/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Herniarin SCHEMBL61221 | 0.92 | CA12 (1.00) | KDM4EALDH1A1CA9CA12HPGD | |
| Herniarin SCHEMBL17629468 | 0.92 | CA12 (1.00) | KDM4EALDH1A1CA9CA12HPGD | |
| Herniarin SCHEMBL29437733 | 0.92 | CA12 (1.00) | KDM4EALDH1A1CA9CA12HPGD | |
| Herniarin SCHEMBL17113785 | 0.90 | CA12 (0.96) | KDM4EALDH1A1CA9CA12HPGD | |
| Herniarin SCHEMBL22654644 | 0.88 | KDM4E (0.79) | KDM4EALDH1A1CA9CA12HPGD | |
| Herniarin SCHEMBL6259517 | 0.87 | CA12 (0.84) | KDM4EALDH1A1CA9CA12HPGD | |
| Herniarin SCHEMBL16752507 | 0.84 | CA12 (0.84) | KDM4EALDH1A1CA9CA12HPGD | |
| 7-Acetoxycoumarin SCHEMBL1827872 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1CA9CA12HPGD | |
| Herniarin SCHEMBL62963 | 0.80 | CA12 (0.77) | KDM4EALDH1A1CA9CA12HPGD | |
| SCHEMBL1108372 | 0.80 | CYP2A6 (1.00) | KDM4EALDH1A1CA9CA12HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611439-B2 | Ionic self-assembling peptides | 3-D MATRIX, LTD. (JP) | 2026-04-28 | — | — | US | claimed |
| CN-112368295-B | Ionic self-assembled peptides | 立美基股份有限公司 | 2025-03-21 | — | — | CN | claimed |
| US-20230241157-A1 | IONIC SELF-ASSEMBLING PEPTIDES | 3-D MATRIX, LTD. (JP) | 2023-08-03 | — | — | US | claimed |
| US-20230226142-A1 | IONIC SELF-ASSEMBLING PEPTIDES | 3-D MATRIX, LTD. (JP) | 2023-07-20 | — | — | US | claimed |
| US-11617778-B2 | Ionic self-assembling peptides | 3-D MATRIX, LTD. (JP) | 2023-04-04 | — | — | US | claimed |
| EP-3914706-A1 | METHODS AND COMPOSITIONS OF ACCELERATING REACTIONS FOR POLYPEPTIDE ANALYSIS AND RELATED USES | Encodia, Inc. (US) | 2021-12-01 | — | — | EP | claimed |
| CN-113557299-A | Methods and compositions for accelerating polypeptide analysis reactions and related uses | ENCODIA 公司 | 2021-10-26 | — | — | CN | claimed |
| EP-3818071-A2 | IONIC SELF-ASSEMBLING PEPTIDES | 3-D Matrix, Ltd. (JP) | 2021-05-12 | — | — | EP | claimed |
| CN-112368295-A | Ionic self-assembling peptides | 立美基股份有限公司 | 2021-02-12 | — | — | CN | claimed |
| CN-112272703-A | Kits for assays employing nucleic acid encoding and/or labeling | ENCODIA有限公司 | 2021-01-26 | — | — | CN | claimed |
| WO-2020154208-A1 | METHODS AND COMPOSITIONS OF ACCELERATING REACTIONS FOR POLYPEPTIDE ANALYSIS AND RELATED USES | Encodia, Inc. (US) | 2020-07-30 | — | — | WO | claimed |
| WO-2020008377-A2 | IONIC SELF-ASSEMBLING PEPTIDES | 3-D MATRIX, LTD. (JP) | 2020-01-09 | — | — | WO | claimed |
| EP-3452591-A1 | MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING | Encodia, Inc. (US) | 2019-03-13 | — | — | EP | claimed |
| WO-2017192633-A9 | MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING | PROCURE LIFE SCIENCES INC. (US) | 2017-12-14 | — | — | WO | claimed |
| WO-2017192633-A1 | MACROMOLECULE ANALYSIS EMPLOYING NUCLEIC ACID ENCODING | PROCURE LIFE SCIENCES INC. (US) | 2017-11-09 | — | — | WO | claimed |
| EP-1995256-A1 | EPHA2 T-cell epitope agonists and uses therefor | University of Pittsburgh of the Commonwealth System of Higher Education (US) | 2008-11-26 | — | — | EP | claimed |
| EP-1651671-A2 | EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFOR | UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-05-03 | — | — | EP | claimed |
| US-20060019899-A1 | EphA2 T-cell epitopes and uses therefor | UNIVERSITY OF PITTSBURGH (US) | 2006-01-26 | — | — | US | claimed |
| US-20050048550-A1 | EphA2 T-cell epitope agonists and uses therefor | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-03-03 | — | — | US | claimed |
| WO-2005012350-A2 | EPHA2 T-CELL EPITOPE AGONISTS AND USES THEREFOR | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12611439-B2 | Ionic self-assembling peptides | QPCTL, GLUL, VIP | KDM4E 1583/4885ALDH1A1 3386/4885CA9 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.